KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Assets: 2010-2025

Historic Current Assets for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $562.8 million.

  • Pacira BioSciences' Current Assets fell 18.44% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.8 million, marking a year-over-year decrease of 18.44%. This contributed to the annual value of $745.1 million for FY2024, which is 46.11% up from last year.
  • Pacira BioSciences' Current Assets amounted to $562.8 million in Q3 2025, which was down 24.53% from $745.6 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Current Assets peaked at $866.0 million during Q4 2021, and registered a low of $376.1 million during Q1 2023.
  • Its 3-year average for Current Assets is $585.6 million, with a median of $562.8 million in 2025.
  • Per our database at Business Quant, Pacira BioSciences' Current Assets soared by 73.88% in 2021 and then crashed by 43.61% in 2023.
  • Pacira BioSciences' Current Assets (Quarterly) stood at $866.0 million in 2021, then plummeted by 42.46% to $498.3 million in 2022, then grew by 2.34% to $510.0 million in 2023, then surged by 46.11% to $745.1 million in 2024, then decreased by 18.44% to $562.8 million in 2025.
  • Its Current Assets stands at $562.8 million for Q3 2025, versus $745.6 million for Q2 2025 and $760.0 million for Q1 2025.